CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
- 2 November 2023
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 142 (18) , 1543-1555
Abstract
A strategy combining targeted therapies is effective in B-cell lymphomas (BCL), such as mantle cell lymphoma (MCL), but acquired resistances remain a recurrent issue. In this study, we performed integrative longitudinal genomic and single-cell RNA-sequencing analyses of patients with MCL who were treated with targeted therapies against CD20, BCL2, and Bruton tyrosine kinase (OAsIs trial). We revealed the emergence of subclones with a selective advantage against OAsIs combination in vivo and showed that resistant cells were characterized by B-cell receptor (BCR)–independent overexpression of NF-κB1 target genes, especially owing to CARD11 mutations. Functional studies demonstrated that CARD11 gain of function not only resulted in BCR independence but also directly increased the transcription of the antiapoptotic BCL2A1, leading to resistance against venetoclax and OAsIs combination. Based on the transcriptional profile of OAsIs-resistant subclones, we designed a 16-gene resistance signature that was also predictive for patients with MCL who were treated with conventional chemotherapy, underlying a common escape mechanism. Among druggable strategies to inhibit CARD11-dependent NF-κB1 transduction, we evaluated the selective inhibition of its essential partner MALT1. We demonstrated that MALT1 protease inhibition led to a reduction in the expression of genes involved in OAsIs resistance, including BCL2A1. Consequently, MALT1 inhibition induced synergistic cell death in combination with BCL2 inhibition, irrespective of CARD11 mutational status, both in vitro and in vivo. Taken together, our study identified mechanisms of resistance to targeted therapies and provided a novel strategy to overcome resistance in aggressive BCL. The OAsIs trial was registered at www.clinicaltrials.gov #NCT02558816.Keywords
This publication has 53 references indexed in Scilit:
- Postibrutinib outcomes in patients with mantle cell lymphomaBlood, 2016
- Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphomaOncotarget, 2015
- Germline CARD11 Mutation in a Patient with Severe Congenital B Cell LymphocytosisJournal of Clinical Immunology, 2014
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481SBTKMutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaCancer Discovery, 2014
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphomaNature Medicine, 2013
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBlood, 2013
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Congenital B cell lymphocytosis explained by novel germline CARD11 mutationsJournal of Experimental Medicine, 2012
- The predictive significance of CD20 expression in B-cell lymphomasDiagnostic Pathology, 2011
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell LymphomaScience, 2008